Results 21 to 30 of about 19,833 (262)

DPP-4 inhibitor attenuates toxic effects of indoxyl sulfate on kidney tubular cells. [PDF]

PLoS ONE, 2014
Diabetic nephropathy is a common causative factor of chronic kidney disease (CKD). DPP-4 inhibitor has the ability to improve kidney function and renal microvasculature.
Wei-Jie Wang, Chen-Hung Chang, Mao-Feng Sun, Sheng-Feng Hsu, Ching-Sung Weng   +4 more
doaj   +1 more source

The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in human umbilical vein endothelial cells

Journal of Pharmacological Sciences, 2017
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral hypoglycemic agents for patients with type 2 diabetes mellitus and have potential antiatherosclerotic properties.
Akari Nagamine, Hiroshi Hasegawa, Naoko Hashimoto, Tomoko Yamada-Inagawa, Masanori Hirose, Yuka Kobara, Hiroyuki Tadokoro, Yoshio Kobayashi, Hiroyuki Takano   +8 more
doaj   +1 more source

All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes

BMC Endocrine Disorders, 2019
Background Dipeptidyl peptidase-4 (DPP-4) inhibitors could effectively reduce HbA1C and postprandial hyperglycemia and could incur only minimal danger of hypoglycemia.
Fu-Shun Yen, Jen-Huai Chiang, Chii-Min Hwu, Yu-Hsin Yen, Boniface J. Lin, James Cheng-Chung Wei, Chih-Cheng Hsu   +6 more
doaj   +1 more source

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication

Clinical Case Reports, 2020
We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation.
Yasutake Shinohara, Toshie Iijima, Shintaro Sakurai, Teruo Jojima, Eriko Ohira, Shujiro Hayashi, Isao Usui, Ken Igawa, Yoshimasa Aso   +8 more
doaj   +1 more source

The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure

Journal of Pharmacological Sciences, 2017
Dipeptidyl peptidase-4 (DPP-4) inhibitors are hypoglycemic agents. DPP-4 inhibitor has cardioprotective effects after transverse aortic constriction (TAC), but role of DPP-4 on cardiac fibrosis after TAC is not well known.
Masanori Hirose, Hiroyuki Takano, Hiroshi Hasegawa, Hiroyuki Tadokoro, Naoko Hashimoto, Genzo Takemura, Yoshio Kobayashi   +6 more
doaj   +1 more source

Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study

Frontiers in Endocrinology, 2021
AimAt present, daily DPP-4 inhibitors are quite frequently prescribed in subjects with type 2 diabetes mellitus (T2DM). Recently, it has been drawing much attention that once-weekly incretin-based injection dulaglutide was developed.
Junpei Sanada, Tomohiko Kimura, Masashi Shimoda, Akiko Tomita, Yoshiro Fushimi, Tomoe Kinoshita, Atsushi Obata, Seizo Okauchi, Hidenori Hirukawa, Kenji Kohara, Fuminori Tatsumi, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto   +14 more
doaj   +1 more source

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin [PDF]

Diabetes & Metabolism Journal, 2015
BackgroundDipeptidyl peptidase-4 (DPP-4) inhibitor add-on therapy is a new option for patients with inadequately controlled type 2 diabetes who are taking combined metformin and sulfonylurea (SU).
Ye An Kim, Won Sang Yoo, Eun Shil Hong, Eu Jeong Ku, Kyeong Seon Park, Soo Lim, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi   +9 more
doaj   +1 more source

DPP-4 Inhibitors—Renoprotection in Diabetic Nephropathy? [PDF]

Diabetes, 2014
There is no doubt that rates of chronic kidney disease are escalating and that this rise is the main contributor to the increasing prevalence of diabetic nephropathy. It is also clear that the increase in kidney failure continues despite tight blood glucose and blood pressure control, as well as renin-angiotensin system blockade.
Usha, Panchapakesan, Carol A, Pollock
openaire   +2 more sources

Cardiovascular effects of the DPP-4 inhibitors

Diabetes and Vascular Disease Research, 2012
Type 2 Diabetes continues to rise in prevalence throughout the globe, and cardiovascular diseases remain the most common cause of morbidity and mortality among patients. Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents whose effect is mediated through the incretin hormones, GLP-1 and GIP.
Tessey, Jose, Silvio E, Inzucchi
openaire   +2 more sources

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors

World Journal of Diabetes, 2022
SGLT-2 inhibitors (SGLT-2Is) have significantly improved cardio-renal outcomes and are preferred agents in people with cardiovascular diseases, heart failure, and diabetic kidney disease. Similarly, GLP-1 receptor agonists (GLP-1RAs) have significantly improved atherosclerotic cardiovascular outcomes. To this end, DPP-4 inhibitors (DPP-4Is) are cardiac-
Singh, Awadhesh Kumar, Singh, Ritu
openaire   +2 more sources